Stockscreener 앱 받기
70.21
0.54%
0.38
시간 외 거래:
70.21
전일 마감가:
$69.83
열려 있는:
$70.12
하루 거래량:
692.37K
Relative Volume:
1.50
시가총액:
$2.68B
수익:
-
순이익/손실:
$-241.60M
주가수익비율:
-10.61
EPS:
-6.6167
순현금흐름:
$-201.34M
1주 성능:
+4.40%
1개월 성능:
+5.01%
6개월 성능:
-19.75%
1년 성능:
+40.28%
1일 변동 폭
$69.14
$71.81
1주일 범위
$67.02
$71.81
52주 변동 폭
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
명칭
Disc Medicine Inc
전화
(617) 674-9274
주소
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
70.21 | 2.68B | 0 | -241.60M | -201.34M | -6.6167 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-03 | 재개 | Stifel | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-11 | 재개 | Raymond James | Strong Buy |
| 2025-02-27 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-22 | 개시 | Wells Fargo | Overweight |
| 2024-04-01 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | 개시 | H.C. Wainwright | Buy |
| 2023-05-17 | 개시 | Raymond James | Outperform |
| 2023-04-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-21 | 개시 | Stifel | Buy |
| 2023-04-20 | 개시 | Morgan Stanley | Overweight |
| 2023-03-23 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), ... - Caledonian Record
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Disc Medicine (IRON) Study update Summary - Quartr
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic OutlookSlideshow (NASDAQ:IRON) 2026-06-15 - Seeking Alpha
IRON: Bitopertin and selcodebart show strong efficacy in EPP and MF anemia, with pivotal data due Q4 2026 - TradingView
IRON: Durable anemia responses and improved outcomes seen in Phase 2 trials for DISC-0974 and bitopertin - TradingView
Disc Medicine, Inc. $IRON Shares Sold by First Turn Management LLC - MarketBeat
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - The Berkshire Eagle
NEXTBio Capital Management LP Takes $3.40 Million Position in Disc Medicine, Inc. $IRON - MarketBeat
Nicholas Investment Partners LP Sells 39,921 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine, Inc. $IRON Stock Position Lowered by Frazier Life Sciences Management L.P. - MarketBeat
Disc Medicine, Inc. $IRON Shares Sold by Atlas Venture Life Science Advisors LLC - MarketBeat
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Disc Medicine reports positive data for hematology pipeline at EHA 2026 - grafa.com
Disc Medicine presents trial data for blood disorder treatments - Investing.com
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting - The Manila Times
Disc Medicine Announces Promising RALLY-MF and HELIOS Trial Data at EHA Annual Meeting - Quiver Quantitative
Anemia and light-tolerance gains seen in Disc Medicine studies - Stock Titan
Disc Medicine (IRON) Is Down 8.6% After Mixed Trial Success And FDA Setback What's Changed - Sahm
IRON Reiterated by Wedbush -- Price Target Maintained at $88.00 - GuruFocus
Wedbush Reiterates Outperform Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Wedbush Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $88 - Moomoo
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Disc Medicine aligns with FDA on path for bitopertin approval By Investing.com - Investing.com Australia
Disc Medicine, FDA agree on approval path for rare disease drug - Seeking Alpha
Disc Medicine aligns with FDA on path for bitopertin approval - Investing.com
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria - The Manila Times
Bitopertin EPP trial measures pain-free time in sunlight - Stock Titan
BNP Paribas Financial Markets Has $9.70 Million Stock Position in Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
Assessing Disc Medicine (IRON) Valuation After New Trial Data And Expanded Access Program News - Sahm
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - ACCESS Newswire
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
Liquidity Mapping Around (IRON) Price Events - Stock Traders Daily
Diamond Blackfan Anemia Market Unlocking New Revenue - openPR.com
Medpace Deadline: MEDP Investors with Losses in Excess of $100K Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit - PR Newswire
BRTX: Advancing late-stage cell therapies for spine, metabolic, and aesthetic markets with strong IP - TradingView
IRON: Bitopertin advances toward pivotal data and regulatory milestones, targeting broad anemia indications - TradingView
Program provides early access to experimental EPP treatment - Porphyria News
Truist Financial Maintains Disc Medicine(IRON.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Disc Medicine(IRON.US), With a Forecast Between $100 to $118 - Moomoo
Stifel reiterates Disc Medicine stock rating on anemia trial data By Investing.com - Investing.com South Africa
Stifel reiterates Disc Medicine stock rating on anemia trial data - Investing.com
Disc Medicine (IRON) Reports Promising Results from RALLY-MF Pha - GuruFocus
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Experimental anemia drug cuts transfusions in myelofibrosis trial - Stock Titan
How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients - Yahoo Finance
Disc Medicine Launches Expanded Access Program for Bitopertin for Epp Patients - marketscreener.com
Disc Medicine launches expanded access program for bitopertin By Investing.com - Investing.com South Africa
Disc Medicine launches expanded access program for bitopertin - Investing.com
Disc Medicine Inc (IRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Disc Medicine Inc 주식 (IRON) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Savage William Jacob | Chief Medical Officer |
Apr 13 '26 |
Sale |
66.38 |
5,731 |
380,449 |
79,480 |
| Franchi Jean M. | Chief Financial Officer |
Apr 14 '26 |
Sale |
69.24 |
6,257 |
433,234 |
64,333 |
| Franchi Jean M. | Chief Financial Officer |
Apr 13 '26 |
Sale |
69.00 |
400 |
27,600 |
70,590 |
2.60%
0.94%
자본화:
|
볼륨(24시간):